Clinical Trial Update: SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma [Phase 2]

View source ↗

Summary

Phase II trial of Nab-Sirolimus for epithelioid hemangioendothelioma; the study (SARC046) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelioid Hemangioendothelioma

Drugs mentioned

• nab-sirolimus (sirolimus (nanoparticle albumin-bound formulation))

Snippet

Sponsor: Sarcoma Alliance for Research through Collaboration | Conditions: Epithelioid Hemangioendothelioma (EHE) | Phase 2 | Status: RECRUITING